Moderna: Said Signed MoU And Land Collaboration Agreement To Research, Develop And Manufacture mRNA Medicines In China; Said Medicines Produced Under This Agreement Will Be Exclusively For The Chinese People And Will Not Be Exported
Portfolio Pulse from Charles Gross
Moderna has signed a Memorandum of Understanding (MoU) and a collaboration agreement to research, develop, and manufacture mRNA medicines in China. The medicines produced under this agreement will be exclusively for the Chinese people and will not be exported.
July 05, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The agreement between Moderna and China could potentially impact the iShares China Large-Cap ETF (FXI), depending on the success of the medicines produced.
The agreement could potentially impact the iShares China Large-Cap ETF (FXI), as Moderna is a significant player in the healthcare sector. However, the impact will depend on the success of the medicines produced and their acceptance in the Chinese market.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Moderna's new agreement to produce mRNA medicines in China could potentially boost its revenues and market presence in the country.
The agreement allows Moderna to tap into the Chinese market, which could significantly increase its revenues and market presence. However, the impact on the stock price will depend on the success of the research and development, and the acceptance of the medicines by the Chinese market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100